Skip to main content
https://pbs.twimg.com/media/F-2pBcdWMAE03EM.png
Another infusion option for axSpA! INVIGORATE-1: Phase 3 RCT of IV Secukinumab in axSpA Efficacious - ASAS40 response sustained thru 52 weeks Safety profile similar to subq version @RheumNow #ACR23 Abs#2545 https://t.co/biC8p3p6dl
Robert B Chao, MD
14-11-2023
×